RSS | Login | Register

XYZAL ORAL SOLUTION

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare XYZAL ORAL SOLUTION to:

XYZAL (levocetirizine) 0.5mg/mL oral solution by UCB and Sanofi Aventis

Generic Name for XYZAL ORAL SOLUTION

Levocetirizine dihydrochloride 0.5mg/mL.

Legal Classification:

Pharmacological Class for XYZAL ORAL SOLUTION

Antihistamine.

Manufacturer of XYZAL ORAL SOLUTION

UCB and Sanofi Aventis

Indications for XYZAL ORAL SOLUTION

Seasonal allergic rhinitis (for patients ≥2 years old). Perennial allergic rhinitis, chronic idiopathic urticaria (for patients ≥6 months old).

Adult dose for XYZAL ORAL SOLUTION

2.5mg–5mg once daily in the PM. Renal dysfunction: CrCl 50–80mL/min: 2.5mg once daily; CrCl 30–50mL/min: 2.5mg every other day; CrCl 10–30mL/min: 2.5mg twice per week (every 3–4 days); CrCl <10 mL/min or hemodialysis: contraindicated.

Children's dosing for XYZAL ORAL SOLUTION

<6mos: not recommended. 6mos–5yrs: max 1.25mg once daily in the PM. 6–11yrs: max 2.5mg once daily in the PM. Renal dysfunction: contraindicated.

Also:

XYZAL

Contraindications for XYZAL ORAL SOLUTION

End-stage renal disease (CrCl <10mL/min) or hemodialysis. Impaired renal function (<12yrs of age).

Warnings/Precautions for XYZAL ORAL SOLUTION

Do not exceed recommended dose. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for XYZAL ORAL SOLUTION

Avoid alcohol, other CNS depressants. May be potentiated by theophylline. Potentiated by ritonavir.

Adverse Reactions for XYZAL ORAL SOLUTION

Adults: somnolence, nasopharyngitis/pharyngitis, fatigue, dry mouth. Children: pyrexia, somnolence, cough, epistaxis, diarrhea, vomiting, otitis media.

How is XYZAL ORAL SOLUTION supplied?

Tabs—90
Soln—150mL

Related Disease:

Allergic rhinitis~systemic products

Allergy~systemic antiallergic drugs

Urticaria~antihistamines

McNeil Consumer Healthcare product supply update

June 25, 2010

McNeil Consumer Healthcare announced that it does not anticipate having sources of supply for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility before the end of 2010.

Vicks Sinex VapoSpray 4-Hour Decongestant Nasal Spray recalled

June 24, 2010

Procter & Gamble announced a voluntary nationwide recall of Vicks Sinex VapoSpray 4-Hour Decongestant Nasal Spray (oxymetazoline HCl).

McNeil recalls Benadryl Allergy Ultratab and Extra Strength Tylenol Rapid Release Gels

June 16, 2010

McNeil Consumer Healthcare has expanded its January 15, 2010 recall to include four lots of Benadryl Allergy (diphenhydramine) Ultratab Tablets and one lot of Extra Strength Tylenol (acetaminophen) Rapid Release Gels.

FDA warns against swallowing topical Benadryl gel

May 12, 2010

The FDA is warning consumers about potentially serious side effects from mistakenly swallowing McNeil Consumer & Specialty Pharmaceuticals' Benadryl (diphenhydramine) Extra Strength Itch Stopping Gel.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.